Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Clinical trial NCT03822117 · TERMINATED
Trial details
- NCT number
- NCT03822117
- Sponsor
- Incyte Corporation
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-17
- Primary completion
- 2022-03-29
- Enrollment
- 111
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.